◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › MANE

Veradermics, Incorporated (MANE) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-20

Veradermics, Incorporated (MANE) operates in the Biotechnology industry and is headquartered in New Haven, United States with about 24 employees. Its market capitalization is roughly $5 billion. In the fiscal year ended 2025-12-31, MANE reported $0M in revenue and ($70M) in net income.

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.

Interactive charts & full statements →

MANE Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-31
Total Revenue$0M$0M$0M
Operating Income (EBIT)($72M)($26M)($17M)
Net Income($70M)($26M)($16M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MANE Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-03-312024-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($30M)($23M)($13M)($6M)
Net Income($27M)($22M)($12M)($6M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MANE Free Cash Flow History

MANE Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-31
Total Assets$153M$56M$18M
Total Liabilities$274M$104M$40M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MANE viewer.

Other Companies in Biotechnology

← MANAll stocksMANH →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.